OGN (Organon) Ending Cash Position: $1,116 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OGN Organon & Co OGN
71 GF Score
Price $13.49
GF Value $14.53
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Organon Ending Cash Position?

Organon OGN -0.22% 71 Ending Cash Position is $1,116 Mil as of Mar. 2026. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.53 (Fairly Valued). The stock has 10 warning signs investors should review.

Organon's Ending Cash Position for the quarter that ended in Mar. 2026 was $1,116 Mil.

Organon's quarterly Ending Cash Position declined from Sep. 2025 ($672 Mil) to Dec. 2025 ($574 Mil) but then increased from Dec. 2025 ($574 Mil) to Mar. 2026 ($1,116 Mil).

Organon's annual Ending Cash Position declined from Dec. 2023 ($693 Mil) to Dec. 2024 ($675 Mil) and declined from Dec. 2024 ($675 Mil) to Dec. 2025 ($574 Mil).

Organon Ending Cash Position Related Terms

Organon Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Organon's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organon Ending Cash Position Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 737.00 706.00 693.00 675.00 574.00

Organon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 547.00 599.00 672.00 574.00 1,116.00
OGN
71GF Score
Organon & Co OGN
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organon Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Organon's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=675+-101
=574

Organon's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=574+542
=1,116

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1,116 Mil mean?
Organon (OGN) has a Ending Cash Position of $1,116 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Organon and its competitors.
Is Organon's Ending Cash Position too high?
Organon's current Ending Cash Position is $1,116 Mil. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Ending Cash Position compare to AMRN and SCLX?
Organon's Ending Cash Position of $1,116 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Organon and its competitors. Organon's current Ending Cash Position is $1,116 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.53, compared to a current price of $13.49 — trading 7.2% below its estimated fair value. The current Ending Cash Position is $1,116 Mil. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Organon (OGN), the current Ending Cash Position is $1,116 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organon (OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be undervalued. The current stock price of $13.49 is trading 7.2% below its estimated GF Value™ of $14.53. GuruFocus considers Organon to be Fairly Valued.

Key valuation signals for OGN:

  • Ending Cash Position: $1,116 Mil
  • GF Value™: $14.53 vs. price of $13.49 (7.2% below fair value)
  • GF Score™: 71/100 with 10 warning signs

No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score

Get the complete analysis for OGN

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.49
Price
$14.53
GF Value